Streetbeat News

QSI

Quantum-Si incorporated

https://www.quantum-si.com

Industry

Biotechnology

Quantum-Si incorporated, a life sciences company, develops a single molecule detection platform for sample preparation and sequencing. It offers a proprietary single molecule detection platform for use in semiconductor industry to field proteomics to enable next generation protein sequencing. The company was incorporated in 2013 is based in Guilford, Connecticut.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Quantum-Si (NASDAQ:QSI) reported Q2 EPS of $(0.16), beating the $(0.19) estimate, but missed sales estimates with $622K against $680K. EPS improved by 11.11% YoY, and sales increased by 203.41% YoY.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 10:03 pm

Quantum-Si has provided its revenue guidance for FY24, projecting between $3.7 million and $4.2 million, which is slightly below the estimated $4.024 million.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 9:53 pm

Quantum-Si (NASDAQ:QSI) reported Q2 2024 GAAP EPS of $(0.16), meeting analyst expectations. The company achieved quarterly sales of $622 million, significantly surpassing the $679.5 thousand estimate and marking a 303.31K percent increase from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 9:30 pm

Quantum-Si Incorporated (NASDAQ:QSI) announced a presentation on their Next-Generation Protein Sequencing technology at the Festival of Genomics and Biodata. The presentation will focus on detecting disease-relevant proteoforms.

Portfolio Pulse from Benzinga Newsdesk

June 10, 2024 | 1:10 pm

Quantum-Si Incorporated (NASDAQ:QSI) has appointed Chuck Kummeth as the independent Chairman of the Board, effective May 27, 2024. Kummeth brings over 35 years of leadership experience in Life Sciences, having significantly grown Bio-Techne during his tenure as President and CEO.

Portfolio Pulse from Benzinga Newsdesk

May 30, 2024 | 8:47 pm

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterated a Buy rating on Quantum-Si (NASDAQ:QSI) with a maintained price target of $4.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 11:36 am

Quantum-Si forecasts its FY24 revenue to be between $3.7M and $4.2M, which is around the analyst estimate of $4.076M.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 10:07 pm

Quantum-Si reported Q1 2024 earnings with a smaller loss per share of $(0.14) compared to the expected $(0.19), and sales of $457,000, surpassing the $426,500 estimate. This represents a significant improvement over the previous year's performance.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:11 pm

U.S. stocks were lower on Monday, with the Dow Jones index falling over 150 points. EQT Corporation's shares dropped 8.4% after announcing a merger with Equitrans Midstream. Other notable declines include Ventyx Biosciences, MoneyLion Inc., Genie Energy Ltd., and several others, each falling due to various company-specific news such as clinical data reports, quarterly results, and strategic updates.

Portfolio Pulse from Avi Kapoor

March 11, 2024 | 2:37 pm

In Thursday's intraday session, several health care stocks experienced significant movements. Notably, Psyence Biomedical, ZyVersa Therapeutics, Creative Medical Tech, HeartBeam, Ocean Biomedical, and Quantum-Si saw their stock prices increase by over 20%. Conversely, Avid Bioservices, Aptorum Gr, Nexalin Technology, BeyondSpring, PepGen, and Viking Therapeutics faced declines, with some dropping by over 30%. These movements reflect notable volatility within the health care sector.

Portfolio Pulse from Benzinga Insights

March 07, 2024 | 5:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.